You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
恆瑞醫藥(600276.SH)2019年度淨利潤升31.05%至53.28億元 擬10送2派2.3元
格隆匯 03-22 15:32

格隆匯3月20日丨恆瑞醫藥(600276.SH)披露2019年年度報告,實現營業收入232.89億元,同比增長33.70%;歸屬於上市公司股東的淨利潤53.28億元,同比增長31.05%;歸屬於上市公司股東的扣除非經常性損益的淨利潤49.79億元,同比增長30.94%;基本每股收益1.20元,擬每10股派發現金股利2.3元(含税)及送紅股2股。經營活動產生的現金流量淨額38.17億元,同比增長37.58%。

公司2019年各項經濟指標較快增長,主要驅動因素為以下方面:一是創新成果的收穫。創新成果的逐步收穫對公司業績增長起到了拉動作用。

二是公司產品結構優化。隨着公司產品結構調整,以手術麻醉、造影劑為代表的公司非抗腫瘤藥產品在各自治療領域內逐步擴大市場,繼續保持快速增長態勢。未來,公司將繼續穩步推進研發創新和製劑產品的國際化,同時,也將着力於產品結構的優化提升,確保公司業績可持續增長。

公司主營業務涉及藥品研發、生產和銷售,主要產品涵蓋抗腫瘤藥、手術麻醉類用藥、特殊輸液、造影劑、心血管藥等眾多領域。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account